Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Lion TCR logo — company profile

Lion TCR

Founded 2015 Singapore Singapore 18 employees Series B Total: $320.00M Biotechnology, Health Care +1

General Information

Company Name Lion TCR
Founded Year 2015
Location Singapore Singapore
Founders / Decision Makers
Team member
Employees 18
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with Lion TCR. To contact Lion TCR, visit liontcr.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Lion TCR compare?

A PDF of Lion TCR and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Lion TCR soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Lion TCR

Lion TCR is a clinical-stage biotechnology company based in Singapore. Established in 2015, it specializes in the development of TCR-T cell therapy for the treatment of cancers and life-threatening infectious diseases in Asia. With a decade of experience, the company has cultivated extensive expertise in various areas, ranging from basic research to T cell engineering, as well as product development and preclinical/clinical assessments. The team, comprising experts from industry and academia, is dedicated to advancing the immunotherapy products and ensuring their commercialization. The latest milestone for Lion TCR was the CNY300.00M Series B investment secured on 27 June 2023. The investors involved in this significant funding round include Guangzhou Industrial Investment Group, CSPC NARD Capital, and Guangzhou Guoju Venture Capital. This injection of funds is anticipated to further propel the company's mission of revolutionizing the treatment of severe diseases through innovative immunotherapy solutions. Overall, Lion TCR's focused approach, innovative technology, and strategic collaborations position it as a promising contender in the biotechnology and healthcare industries, with potential for significant impact in Asia and beyond.

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B CNY300.00M 3
Guangzhou Industrial Investment Group
Guangzhou Industrial Investment Group, CSPC NARD Capital +1
27 Jun 2023
Series A $20.00M 2
Westlake Venture Partners
Westlake Venture Partners, Yashang Capital
27 May 2018

Lion TCR Alternatives & Competitors

View All Alternatives
Lion TCR vs
Neogene Therapeutics
Neogene Therapeutics The Netherlands

Pushing the frontier by pioneering next-generation engineered T cell receptor therapies for solid ca...

Acquired
45 employees
Biotechnology, Health Care
Lion TCR vs
Celularity Inc.
Celularity Inc. United States

A next-gen Biotech company creating off-the-shelf cellular medicines for Cancer, Infectious, and Deg...

Post-IPO Equity
171 employees
Biotechnology, Health Care
Lion TCR vs
Bioniz, LLC
Bioniz, LLC United States

Pioneering the future of autoimmune and cancer treatment with innovative small peptides and molecule...

Acquired
3 employees
Biotechnology, Health Care
View all alternatives

FAQ About Lion TCR

This clinical-stage biotechnology company focuses on the development of TCR-T cell therapy for cancers and life-threatening infectious diseases in Asia. Over the last ten years, they have built extensive expertise across the entire product development spectrum, including basic research, T cell engin...
Lion TCR was founded in 2015.
Lion TCR is headquartered in Singapore.
Lion TCR operates in Biotechnology, Health Care and Health and Wellness.
Lion TCR has approximately 18 employees.
Lion TCR has completed 2 funding rounds, raising a total of $320.00M. The latest funding stage is Series B.
Top alternatives and competitors to Lion TCR include Neogene Therapeutics, Celularity Inc., Bioniz, LLC, Tmunity Therapeutics, Virion Therapeutics, LLC. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Lion TCR and Neogene Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Lion TCR, https://bouncewatch.com/company/lion-tcr, updated 31 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout